Agios Pharmaceuticals

AGIO

78.89

+0.54

+0.7%

Please Login or Register

Login|Register FREE

Stock Price
Open: 76.15
Prev. Close: 78.35
Low/Hi: 74.52 - 79.35
52-Week: 39.24 - 80.00
Volumes
Equity: 501,755
90-Day Avg: 480,917
Option: 66
90-Day Avg: 505
Volatility
Todays Stock Vol: 75.3
20-Day (HV): 71.0
52-Week (HV): 47.8
30-Day IV: 47.1 -0.2
IV Pct Rank: 27% Subdued
Fundamental
Div. Yield:
Earnings: 16-Feb (Est.)
P/E Ratio:
Market Cap: 3.8 B
Short Int Pct: 0.0%
Pct Held By Inst.: 96.1%
Stock Info
Type: Common
Sector: Healthcare
Industry: Biotechnology

AGIO Company Events

Upcoming Events
Event Event Date Location Info
No Upcoming Events
Past Events
Event Event Date Location Info
36th Annual J.P. Morgan Healthcare Conference Jan 8, 12:30 PM
2017American Society of Hematology(ASH) Annual Meeting Dec 10, 2017 - Dec 11, 2017
26th Annual Credit Suisse Healthcare Conference Nov 7, 2017
Morgan Stanley 15th Annual Global Healthcare Conference Sep 11, 2017
Canaccord Genuity 37th Annual Growth Conference Aug 10, 9:30 AM
American Society of Clinical Oncology (ASCO) Annual Meeting Jun 2, 2017 - Jun 6, 2017
16th Annual Needham Healthcare Conference Apr 4, 9:20 AM
Cowen and Company 37th Annual Health Care Conference Mar 6, 2:00 PM
35th Annual J.P. Morgan Healthcare Conference Jan 9, 2017 San Francisco
2016 American Society of Hematology (ASH) Annual Meeting Dec 3, 2016 - Dec 5, 2016 San Diego
25th Annual Credit Suisse Healthcare Conference Nov 8, 3:30 PM
Morgan Stanley Global Healthcare Conference Sep 13, 2016 New York
Canaccord Genuity 36th Annual Growth Conference Aug 10, 2016
Agios Pharmaceuticals Inc Annual Shareholders Meeting Jun 21, 9:00 AM
Phase 1 Healthy Volunteer Study Company to Host Conference Call Jun 11, 2016
i

Presented from AG-348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase

European Hematology Association (EHA Jun 9, 2016 - Jun 12, 2016 Copenhagen.
i

five abstracts led by Agios and collaborators describing new clinical and preclinical data from the company's rare genetic metabolic disorders program, including three oral presentations, have been accepted for presentation at EHA. AG-348 is in an ongoing Phase 2 study (DRIVE PK) in adults with pyruvate kinase (PK) deficiency. AG-519 is in an ongoing Phase 1 study in healthy volunteers

21st Congress of the European Hematology Association Jun 9, 2016 - Jun 12, 2016 Copenhagen.
i

discuss clinical and preclinical data presented

Cowen Health Care Conference Mar 8, 2016
Leerink Partners 5th Annual Global Healthcare Conference Feb 10, 11:30 AM
34th Annual J.P. Morgan Healthcare Conference Jan 11, 2016 San Francisco
34th Annual J.P. Morgan Healthcare Conference Jan 11, 2016
Credit Suisse 24th Annual Healthcare Conference Nov 10, 2015 Scottsdale, Arizona
Credit Suisse 24th Annual Healthcare Conference Nov 10, 2015
AACR-NCI-EORTC International Conference Nov 5, 2015 - Nov 9, 2015 Boston
i

Chris Bowden M.D., chief medical officer at Agios. "This is an important step toward our long-term vision of making a difference for people with a broad range of hematologic and solid tumor cancers that harbor IDH mutations.

Research and Development (R&D) Day Oct 16, 2015 New York City
Canaccord Genuity 35th Annual Growth Conference Aug 12, 2015 Boston

Wait, Before You Leave...

Want to Know More About AGIO Earnings?

Receive your FREE email to get Wall Street expected earnings moves and daily upcoming earnings alerts!
Market Chameleon